Company Summary:
Terrana Biosciences is one of the latest companies founded through Flagship Pioneering’s venture creation engine, where companies such as Moderna Therapeutics and Evelo Therapeutics were conceived and created. Since Flagship’s founding in 2000, the firm has originated and fostered the development of nearly 100 scientific ventures resulting in $19+ billion in aggregate value, 500+ issued patents, and more than 50 clinical trials for novel therapeutic agents. Arana Biosciences is integrating the latest developments in molecular biology and plant biology to create a new platform technology that enables adaptive, targeted and sustainable solutions in agriculture.
Position Summary:
We are seeking a highly motivated, proactive, and detail-oriented Contract Research Associate, Cloning to join our team and provide technical and bench support for our cloning workflows. This is an opportunity to work with exceptional scientists to develop cutting-edge technology to revolutionize sustainable agriculture. The ideal candidate will have basic knowledge of molecular biology methods, cloning concepts, and a strong desire to learn and grow within the field. You will gain hands-on experience with molecular biology and cloning techniques and will use cutting-edge laboratory automation technologies to perform cloning protocols. You will interface with teams to contribute to a variety of different projects, enabling research in diverse crops. The role requires experience with cloning and with working on a project team. The successful candidate is highly organized, comfortable working in a fast-paced entrepreneurial environment, and desires to be an integral part of a highly collaborative and interdisciplinary team. Excellent communication, record-keeping, and teamwork will be critical.
Key responsibilities include:
Basic qualifications:
Additional Qualifications:
Location: Cambridge, MA
More About Flagship Pioneering
Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $50B in aggregate value. To date, Flagship has deployed over $2.2B in capital toward the founding and growth of its pioneering companies alongside more than $18B of follow-on investments from other institutions. The current Flagship ecosystem comprises transformative companies, including Seres Therapeutics (NASDAQ: MCRB), Indigo Ag, Invaio Sciences, Moderna (NASDAQ: MRNA), Generate Biomedicines, Denali Therapeutics (NASDAQ: DNLI), Senda Biosciences and Foghorn Therapeutics (NASDAQ: FHTX).